Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Deals

July 21 Quick Takes: Turnstone’s $80M round to advance oncolytic virus, TIL programs

Plus: Vedanta, bluebird, Cytokinetics and more

July 22, 2021 12:58 AM UTC

Six months after Turnstone Biologics Corp. acquired Myst Therapeutics Inc. to gain tumor-infiltrating lymphocyte technologies that complement its existing pipeline of oncolytic viruses, the biotech has raised $80 million in a series D round led by PFM Health Sciences and Point72. Also participating are Eventide Asset Management, Citadel-backed Surveyor Capital, Ridgeback Capital Investments, Takeda Ventures Inc., CaaS Capital, JM Family Enterprises Inc., Northleaf Capital Partners and 404 Bio, as well as prior investors Versant Ventures, OrbiMed, F-Prime Capital, Sectoral Asset Management, Sixty Degree Capital, Brace Pharma Capital and Teralys Capital.

Microbiome company Vedanta Biosciences Inc. has completed a $68 million series D round as it prepares to advance lead candidate VE303 into a Phase III trial to treat Clostridioides difficile infection, due to begin in mid-2022. The round includes a $25 million contribution from Pfizer Inc. (NYSE:PFE) that was announced in January. Vedanta also expects to start a Phase II study this half of another therapy, VE202, to treat ulcerative colitis. Magnetar Capital led the new round alongside Verition Fund Management, Fosun Health Capital, co-founder PureTech Health plc (LSE:PRTC; NASDAQ:PRTC), Rock Springs Capital, Skyviews Life Science, JSR Corp., SymBiosis, Shumway Capital, and Seventure Partners’ Health for Life Capital...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article